このエントリーをはてなブックマークに追加
ID 37739
本文ファイル
著者
Ishioka, Shinichi
Hozawa, Soichiro
Hiyama, Keiko
Maeda, Akihiro
Yamakido, Michio
キーワード
Bronchial asthma
Cysteinyl leukotriene receptor antagonist
Pranlukast
Serum eosinophil cationic protein
NDC
医学
抄録(英)
Cysteinyl leukotrienes (cysLTs) are considered to be important mediators involved in bronchial asthma and the ensuing eosinophilic inflammation. We evaluated the effects of pranlukast, a potent and selective cysLT receptor antagonist, on the clinical course and serum eosinophil cationic protein (ECP) levels of 10 asthmatic patients. A four-week administration of pranlukast increased the morning peak expiratory flow (PEF) (p=0.007) and decreased as-needed /3z-agonist use (p=0.021). Changes in the morning PEF inversely correlated with those in the serum ECP levels (r=-0.80, p=0.0057). These results suggest that cysLTs are important mediators involved in eosinophilic inflammation, a major pathophysiologic feature of bronchial asthma in humans.
内容記述
Part of this study was supported by a research grant from the Japanese Ministry of Health and Welfare.
掲載誌名
Hiroshima Journal of Medical Sciences
48巻
4号
開始ページ
105
終了ページ
110
出版年月日
1999-12
出版者
Hiroshima University Medical Press
ISSN
0018-2052
NCID
言語
英語
NII資源タイプ
紀要論文
広大資料タイプ
学内刊行物(紀要等)
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
publisher
部局名
医歯薬学総合研究科
他の一覧